Immunorix

Immunorix is a medicine that helps stimulate the body's immune responses.

Indications Immunorix

It is used to stimulate cellular immune responses when diagnosing weakened immunity due to infectious lesions affecting the urinary system or respiratory organs.

Release form

Released as an oral solution in glass vials with a volume of 7 ml (per 1 dosage). Inside the pack there are 10 vials with solution.

Pharmacodynamics

Pidotimod affects the body by stimulating the processes of cellular immune response, as well as their regulation.

In case of deficiency of T-lymphocytes, which under physiological conditions are coordinators of a specific immune response, the substance pidotimod, partially replacing or enhancing the activity of the thymus, promotes the formation of T-lymphocytes, and in addition, the achievement by these elements of full immune compliance with the required reactions.

At the same time, the drug stimulates the activity of macrophages responsible for the process of absorption of the antigen, and in addition for the presence of this element on the membrane surface - for antigens responsible for histocompatibility. The protective functions of the body in relation to infectious agents depend on the degree of effectiveness of specific cellular, as well as immune and humoral reactions.

The medicinally significant properties of the substance pidotimod are due to the presence of immunostimulating activity in relation to natural immune function, as well as the effect on the production of antibodies, cellular immune response and the production of cytokines.

Pidotimod increases the amount of superoxide anions produced by the body, as well as TNFα and NO (bactericidal effect). The element also stimulates chemotaxis activity and, at the same time, the process of phagocytosis. The drug increases the cytotoxic activity of natural killers.

Pidotimod increases the functional activity of T- and B-lymphocytes, increases the efficiency of inducing an antibody response, and at the same time inhibits the apoptosis process caused by dexamethasone, as well as 12-B-tetradecanoylphorbol-13-acetate and the ionophore group A-23l87 (calcium type).

The drug enhances the non-specific protective function of the body – increasing the production of immunoglobulin category A. In addition, it significantly increases the number of produced cytokines (such as IL-2), as well as γ-interferons.

Pharmacokinetics

Pharmacokinetic tests involving volunteers have demonstrated that high absorption rates are observed after oral administration of the solution. The bioavailability level reaches 45%, the half-life is 4 hours. The drug is excreted in the urine (unchanged substance) - 95% of the dose taken.

The extent and rate of absorption of the drug is significantly reduced when taken with food. After oral administration with food, bioavailability values drop by 50%, and it takes 2 hours longer to reach peak serum levels than when taken on an empty stomach.

The active component is completely excreted in the urine. If the patient has renal failure, the half-life is extended. But even in the case of a severe form of this disease (the creatinine level in plasma is 5 mg/dl), the half-life of the substance lasted no more than 8-9 hours.

Since patients take the drug at intervals of 12 or 24 hours, there is no risk of drug accumulation in case of renal failure.

Dosing and administration

Adult dosage: take the contents of 2 vials (designed for one dose) – 800 mg 2 times a day for 15 days.

Children's dosage sizes (over 3 years): take the contents of 1 bottle (designed for 1 dose) - 400 mg 2 times a day for a period of 15 days.

It is possible to adjust the dose sizes and the duration of the course of application, taking into account the degree of expression of the signs of the disease, as well as its severity. But the course in any case can last no more than 3 months.

To eliminate recurrent infectious lesions in people at risk of developing immunodeficiency (or with a history of it), it is necessary to use: for adults, 800 mg, and for children, 400 mg of solution for a period of 2 months (as a maintenance treatment).

[ 1 ]

Use Immunorix during pregnancy

There is insufficient information on the use of Imunorix in pregnant women to draw conclusions about its safety. Although animal tests did not reveal any negative effects of the drug on reproductive activity, its use during pregnancy is still not recommended.

There is no information on the passage of pidotimod or its breakdown products into breast milk, but it is recommended to refrain from breastfeeding during the period of using the drug - to avoid the effect of pidotimod on the infant.

Contraindications

Main contraindications: hypersensitivity to the components of the drug, as well as children under 3 years of age.

Side effects Immunorix

Taking the solution sometimes causes the following side effects:

• immune disorders: development of rheumatic purpura and uveitis was observed in isolated cases;
• gastrointestinal tract lesions: occasional nausea, abdominal pain or diarrhea;
• lesions of the skin and subcutaneous layers: symptoms of allergic dermatitis appear sporadically (including rashes, urticaria, as well as itching and swelling of the lips).

Interactions with other drugs

Pidotimod does not undergo protein synthesis in plasma. The substance does not undergo metabolic processes, and therefore no pharmacokinetic interactions should be expected.

The drug can interact with drugs that stimulate or slow down lymphocyte activity, or affect immune functions.

Animal tests showed that no adverse reactions were observed when the drug was used in combination with common drugs. The drugs used in the tests included: phenobarbital (a general anesthetic), tolbutamide (a drug that lowers sugar levels), chlorothiazide (a diuretic), warfarin (an anticoagulant), captopril with nifedipine and atenolol (antihypertensive drugs), acetylsalicylates (an analgesic), indomethacin (NSAID), and paracetamol (an antipyretic drug).

[ 2 ], [ 3 ]

Storage conditions

The solution should be stored in a place protected from moisture and sunlight, and out of the reach of small children. The optimal temperature is a maximum of 30°C.

[ 4 ]

Special instructions

Reviews

Immunorix is considered to be quite an effective remedy - medical reviews indicate that it enhances immune responses and increases the body's resistance to invasions of pathogenic microbes (among the properties: resistance to fungi with bacteria, as well as viruses). These reviews are confirmed by laboratory tests and analyses.

Parents often use the medicine to prevent the development of various diseases in children during the seasonal winter-spring periods. Conducting a conservative course of prevention in a child leads to the development of resistance in his body in relation to standard respiratory pathologies, and in addition to this, to an increase in performance at school.

Adults often use the drug to correct immunity during the treatment of urinary system pathologies. The use of Imunorix during the elimination of venereal diseases reduces the treatment course several times. This indicates the high effectiveness of the drug.

Shelf life

Immunorix can be used for a period of 3 years from the date of release of the drug.